Posted by mod198 February - 8 - 2015 ADD COMMENTS

New York, New York (PRWEB) February 07, 2015

The federal multidistrict litigation established for Lipitor lawsuits ( that claim the medication is associated with an increased risk of Type 2 diabetes continues to move forward in the U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. According to court documents, the proceeding’s next Status Conference has been scheduled for Thursday, February 26th at 10:00 a.m. The parties have been directed to submit a Joint Status Report to the Court by February 19th. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)

“Our Firm is pleased to see this proceeding moving forward, as we are representing a number of clients who have filed Lipitor diabetes claims. We look forward to the Conference later this month,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who may have been harmed by Lipitor.

Lipitor Diabetes Litigation

Court records indicate that the litigation surrounding Lipitor and diabetes began to grow in the wake of a U.S. Food & Drug Administration (FDA) alert regarding a possible association between the use of cholesterol-lowering statins and Type 2 diabetes. At the time, the agency said the labels for Lipitor and other statins would be updated to include new information about their potential association with Type 2 diabetes. The FDA was prompted to act by the publication of a study in JAMA: Internal Medicine the previous month which suggested that post-menopausal women treated with statins faced an increased risk of developing new-onset Type 2 diabetes. *

Since then, court records indicate that more than 1,600 Lipitor diabetes claims have been filed in state and federal courts around the country, the majority of which are pending in the federal proceeding underway in South Carolina. Among other things, the lawsuits assert the modifications made to the Lipitor label to comply with the FDA’s 2012 mandate still do not sufficiently inform patients about Lipitor’s association with Type 2 diabetes. The drug’s manufacturer, Pfizer, Inc., is also accused of concealing information about diabetes in order to protect sales of Lipitor.

Lipitor patients who allegedly developed Type 2 diabetes due to the medication may be entitled to compensation from Pfizer. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.

*, JAMA Internal Medicine, January

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have ben able to recover more than $ 3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016


ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com

Related Challenges Press Releases

Tags : , , , , , , , , , , , , , Big Data Challenges

Leave a Reply

You must be logged in to post a comment.